Viking Therapeutics VK2735 maintenance study reports positive topline: up to 97% weight loss maintained with EOW or monthly dosing

The Phase 2 maintenance study met its objectives, showing that after 21 weeks of weekly VK2735 induction (16-19% weight loss), transition to every-other-week or monthly subcutaneous dosing for 12 weeks maintained 83-97% or 82-90% of lost weight, respectively, versus 61% on placebo. GI tolerability during maintenance was comparable to placebo with low discontinuation rates. These data support less frequent dosing regimens for long-term obesity management.

Key facts

Filed: Sep 22, 2026, 11:06 AM
Event: Topline results
Direction: Positive
Company: VKTXViking Therapeutics
Asset: VK2735
Source: SEC 8-K
Confidence: Sourced
continued loss: ~22% at Week 33 (weekly 17.5 mg)
induction weight loss: 16% to 19% vs ~0% placebo at Week 21
maintenance retention eow: 83% to 97% vs 61% placebo at Week 33
maintenance retention monthly: 82% to 90% vs 61% placebo at Week 33

Source excerpt

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens News provided by Viking Therapeutics, Inc. Sep 22, 2026, 07:05 ET Share this article Share to X Share this article Share to X 22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment Up to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months Up to 90% of Weight Loss Maintained Following Transition to Monthly Dosing for Three Months Excellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to Placebo Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , Sept. 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735, the company's dual agonist of the glucagon-like peptide 1 ( GLP-1 ) and glucose-d

SEC 8-K

More on this asset

Oct 6, 2026

07:05 PM

VKTXViking Therapeutics

Viking Therapeutics initiates Part 2 of VK2735 oral/subcutaneous maintenance dosing trial in obesity

Trial registry changeCompany press release